Group 1 - Novartis has agreed to sell its 70.68% stake in Novartis India Ltd. for ₹14.46 billion (approximately $159 million) to a consortium of investors including WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners [1] - The transaction marks the conclusion of a strategic review initiated by Novartis in February 2024 regarding its listed subsidiary [1] - Novartis India Ltd. is primarily responsible for the sales of prescription drugs, generics, and over-the-counter products in the Indian market [1] Group 2 - Following the transaction, Novartis India will advance its business development under new majority ownership [1] - The acquiring consortium has launched a public offer to acquire up to 26% of Novartis India shares at ₹860.84 per share, valuing the offer at approximately ₹5.52 billion [1] - Novartis has clarified that the strategic review does not involve its wholly-owned subsidiary, Novartis Healthcare Pvt. Ltd., which oversees commercial operations in the region [1][2] Group 3 - Prior to the strategic review, Novartis India had signed multiple distribution agreements with local partners, including a collaboration with Dr. Reddy's Laboratories Ltd. to market products such as Voveran and calcium series products in India [1] - The divestiture adjusts the ownership structure of Novartis India while allowing Novartis to retain its infrastructure and research layout in the Indian market [2]